Search
Pegfilgrastim
go.drugbank.com/drugs/DB00019ApprovedInvestigational[A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection. … [A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological
Categories: Compounds used in a research, industrial, or household settingProducts: Pelgraz 6 mg solution for injection in a pre-filled syringe, NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6MLGallamine triethiodide
go.drugbank.com/drugs/DB00483ApprovedWithdrawnA synthetic nondepolarizing blocking drug. … It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigationalin which the patient develops an infection during a period of significant neutropenia. … [L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker.
Warfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalWarfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. … Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic IndexMumps virus strain B level jeryl lynn live antigen
go.drugbank.com/drugs/DB10316ApprovedInvestigationalMumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.
Mixtures: <p>SII MEASLES,MUMPS & RUBELLA VACCINE LIVE ATTENUATED (FREEZE-DRIED) SINGLE DOSE</p>Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements [A31846] … It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors [A31846].
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Enhertu 100 mg IV İnfüzyonluk Çözelti Hazırlamada Kullanılacak Konsantre İçin Toz, 1 ADETOnasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigationalDeveloped by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. … [A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms.
Guselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalGuselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. … IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].
Products: TREMFYA IV